Financial News
A major cancer drugmaker may need to buy its way out of a looming disaster
January 18, 2018 at 13:24 PM EST
Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
